23,476 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Acquired by Algert Global LLC

Algert Global LLC acquired a new stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,476 shares of the company’s stock, valued at approximately $110,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its position in Applied Therapeutics by 198.6% during the 1st quarter. Janus Henderson Group PLC now owns 6,414,642 shares of the company’s stock valued at $43,555,000 after buying an additional 4,266,179 shares during the period. Propel Bio Management LLC boosted its holdings in shares of Applied Therapeutics by 13.7% during the first quarter. Propel Bio Management LLC now owns 6,111,906 shares of the company’s stock worth $41,561,000 after purchasing an additional 736,924 shares during the period. Knoll Capital Management LLC grew its stake in shares of Applied Therapeutics by 1.8% in the first quarter. Knoll Capital Management LLC now owns 5,574,687 shares of the company’s stock worth $37,908,000 after purchasing an additional 100,000 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in Applied Therapeutics by 17.1% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company’s stock valued at $10,676,000 after purchasing an additional 333,278 shares during the last quarter. Finally, StemPoint Capital LP lifted its holdings in Applied Therapeutics by 122.3% in the 1st quarter. StemPoint Capital LP now owns 2,017,016 shares of the company’s stock worth $13,716,000 after buying an additional 1,109,864 shares during the period. Institutional investors own 98.31% of the company’s stock.

Insider Activity

In related news, CEO Shoshana Shendelman sold 300,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $5.98, for a total value of $1,794,000.00. Following the sale, the chief executive officer now owns 5,167,853 shares in the company, valued at $30,903,760.94. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 8.60% of the company’s stock.

Applied Therapeutics Trading Up 4.5 %

Shares of Applied Therapeutics stock opened at $8.57 on Friday. The business has a fifty day simple moving average of $6.58 and a two-hundred day simple moving average of $5.51. The firm has a market capitalization of $984.26 million, a P/E ratio of -5.36 and a beta of 2.04. Applied Therapeutics, Inc. has a 12 month low of $1.79 and a 12 month high of $9.39.

Applied Therapeutics (NASDAQ:APLT) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). The company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $10.00 million. Analysts predict that Applied Therapeutics, Inc. will post -0.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on APLT shares. Royal Bank of Canada reissued an “outperform” rating and set a $12.00 target price on shares of Applied Therapeutics in a research note on Wednesday, July 17th. William Blair upgraded shares of Applied Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Leerink Partners raised their target price on shares of Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Finally, Citigroup boosted their price target on shares of Applied Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $12.50.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.